JP5323720B2 - 眼用薬物送達のためのデバイスおよび方法 - Google Patents

眼用薬物送達のためのデバイスおよび方法 Download PDF

Info

Publication number
JP5323720B2
JP5323720B2 JP2009542994A JP2009542994A JP5323720B2 JP 5323720 B2 JP5323720 B2 JP 5323720B2 JP 2009542994 A JP2009542994 A JP 2009542994A JP 2009542994 A JP2009542994 A JP 2009542994A JP 5323720 B2 JP5323720 B2 JP 5323720B2
Authority
JP
Japan
Prior art keywords
styrene
drug
eye
block copolymer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009542994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513542A5 (enExample
JP2010513542A (ja
Inventor
バーラム アスガリアン，
マスード エー． チョワン，
Original Assignee
アルコン リサーチ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルコン リサーチ， リミテッド filed Critical アルコン リサーチ， リミテッド
Publication of JP2010513542A publication Critical patent/JP2010513542A/ja
Publication of JP2010513542A5 publication Critical patent/JP2010513542A5/ja
Application granted granted Critical
Publication of JP5323720B2 publication Critical patent/JP5323720B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009542994A 2006-12-18 2007-11-08 眼用薬物送達のためのデバイスおよび方法 Expired - Fee Related JP5323720B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85814306P 2006-12-18 2006-12-18
US60/858,143 2006-12-18
PCT/US2007/084009 WO2008076544A2 (en) 2006-12-18 2007-11-08 Devices and methods for ophthalmic drug delivery

Publications (3)

Publication Number Publication Date
JP2010513542A JP2010513542A (ja) 2010-04-30
JP2010513542A5 JP2010513542A5 (enExample) 2013-05-23
JP5323720B2 true JP5323720B2 (ja) 2013-10-23

Family

ID=39265276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542994A Expired - Fee Related JP5323720B2 (ja) 2006-12-18 2007-11-08 眼用薬物送達のためのデバイスおよび方法

Country Status (13)

Country Link
US (2) US20080145406A1 (enExample)
EP (1) EP2091481A2 (enExample)
JP (1) JP5323720B2 (enExample)
KR (1) KR20090098870A (enExample)
CN (2) CN101563051A (enExample)
AR (1) AR063619A1 (enExample)
AU (1) AU2007334248B2 (enExample)
BR (1) BRPI0720431A2 (enExample)
CA (1) CA2670944A1 (enExample)
MX (1) MX2009006146A (enExample)
TW (1) TW200829293A (enExample)
WO (1) WO2008076544A2 (enExample)
ZA (1) ZA200903649B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
JP4869930B2 (ja) * 2003-08-26 2012-02-08 ヴィスタ サイエンティフィック エルエルシー 眼科薬物供給装置
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US9510844B2 (en) 2007-11-13 2016-12-06 Mgd Innovations, Llc Gland or duct diagnostic and treatment methods and related apparatus
WO2009064834A2 (en) 2007-11-13 2009-05-22 Maskin Steven L Meibomian gland intraductal diagnostic and treatment methods and related apparatus
US9873001B2 (en) 2008-01-07 2018-01-23 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US10022558B1 (en) 2008-01-07 2018-07-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CA2728623A1 (en) * 2008-06-24 2010-01-21 Qlt Plug Delivery, Inc. Combination treatment of glaucoma
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4, Inc. ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
WO2010101758A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. Peri-corneal drug delivery device
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
AU2010256558B2 (en) 2009-06-03 2013-10-03 Forsight Labs, Llc Anterior segment drug delivery
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
CN103619327A (zh) * 2010-12-29 2014-03-05 嘉德治疗股份有限公司 眼部给药体系
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
US9102105B2 (en) 2011-09-13 2015-08-11 Vista Scientific Llc Method for forming an ocular drug delivery device
RU2740680C2 (ru) 2011-09-14 2021-01-19 Форсайт Вижн5, Инк. Глазное вкладочное устройство и способы
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
US9510972B2 (en) * 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US9642742B2 (en) 2012-10-02 2017-05-09 Harold D. Mansfield Eye drop applicator and drop transfer method
EP2911623B1 (en) 2012-10-26 2019-08-14 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2014241163B2 (en) 2013-03-28 2018-09-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
KR102948178B1 (ko) 2013-07-12 2026-04-10 아스텔라스 유에스 엘엘씨 안과적 질환을 치료하거나 예방하기 위한 방법
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
RU2695563C2 (ru) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Способ и устройство для доставки глазного имплантата
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9931306B2 (en) * 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye
JP7037360B2 (ja) 2014-11-10 2022-03-16 フォーサイト・ビジョン フォー・インコーポレーテッド 拡張可能な薬物送達デバイス
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US10603210B1 (en) 2017-02-02 2020-03-31 Mgd Innovations, Llc Meibomian gland probing with blood product injection
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206692A1 (es) * 1972-12-27 1976-08-13 Alza Corp Agente dispensador de liberacion sostenida de substancias activas
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
ZA991938B (en) * 1998-03-11 2000-09-10 Dow Chemical Co Structures and fabricated articles having shape memory made from alpha-olefin/vinyl or vinylidene aromatic and/or hindered aliphatic vinyl or vinylidene interpolymers.
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
ATE414494T1 (de) * 1999-10-21 2008-12-15 Alcon Inc Medikamentenzuführeinrichtung
ATE404140T1 (de) * 2000-08-30 2008-08-15 Univ Johns Hopkins Vorrichtung zur intraokularen wirkstoffverabreichung
EP1404295B1 (en) * 2001-01-03 2007-10-10 Bausch & Lomb Incorporated Sustained release drug delivery devices with coated drug cores
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
ES2244361T1 (es) * 2002-08-05 2005-12-16 Alcon, Inc. Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad.
US20040219198A1 (en) * 2003-05-01 2004-11-04 3M Innovative Properties Company Transdermal drug delivery device with multilayer backing
JP5009623B2 (ja) * 2003-12-05 2012-08-22 イノレーン リミティド ライアビリティ カンパニー 改良された眼内レンズ
WO2005055972A2 (en) * 2003-12-09 2005-06-23 Nanon A/S A drug delivery device and a method of producing it
US20050181015A1 (en) * 2004-02-12 2005-08-18 Sheng-Ping (Samuel) Zhong Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles
CN1964748A (zh) * 2004-04-06 2007-05-16 苏莫迪克斯公司 用于生物活性剂的涂料组合物
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2006124749A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug delivery system with barrier against antagonist exposure
US10029034B2 (en) * 2005-12-15 2018-07-24 CARDINAL HEALTH SWITZERLAND 515 GmbH Drug-eluting articles with improved drug release profiles

Also Published As

Publication number Publication date
ZA200903649B (en) 2010-08-25
AU2007334248B2 (en) 2013-06-27
MX2009006146A (es) 2009-06-19
BRPI0720431A2 (pt) 2013-12-31
KR20090098870A (ko) 2009-09-17
US20100266664A1 (en) 2010-10-21
WO2008076544A2 (en) 2008-06-26
WO2008076544A3 (en) 2008-08-28
JP2010513542A (ja) 2010-04-30
US20080145406A1 (en) 2008-06-19
AU2007334248A1 (en) 2008-06-26
TW200829293A (en) 2008-07-16
CN103622778A (zh) 2014-03-12
EP2091481A2 (en) 2009-08-26
CA2670944A1 (en) 2008-06-26
CN101563051A (zh) 2009-10-21
AR063619A1 (es) 2009-02-04

Similar Documents

Publication Publication Date Title
AU2007334248B2 (en) Devices and methods for ophthalmic drug delivery
CN101984745B (zh) 用于持续释放治疗药物的药物核心
Chiang et al. The suprachoroidal space as a route of administration to the posterior segment of the eye
AU2004237774B2 (en) Implantable controlled release bioactive agent delivery device
US8003124B2 (en) Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
JP2022119912A (ja) ヒト被験体における眼部障害の処置のための方法およびデバイス
JP6602761B2 (ja) 眼科用デバイス
JP2016127945A (ja) １つまたは複数の薬剤の徐放性送達
JP2019501200A (ja) 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス
Beeley et al. Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system
AU2005229667B2 (en) Controlled release bioactive agent delivery device
Boyer Drug Delivery to the Posterior Segment: An Update
HK1155104B (en) Drug cores for sustained release of therapeutic agents
HK1189521B (en) Drug cores for sustained release of therapeutic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130401

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130717

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees